礼来减重药片试验结果不及预期,股价大跌14%

金十数据
Aug 08

这款药片在经过一年多的治疗后,帮助受试者平均减重约12%。这一结果可能为这种注射剂替代品在明年上市扫清障碍,但减重幅度未达到华尔街的预期。尽管如此,礼来公司仍上调了全年盈利预期,因为受其减重和糖尿病治疗药物持续强劲需求的带动,公司最新季度营收大幅增长。这款名为Orforglipron的药片一旦获批,有望成为热销产品。摩根士丹利分析师此前在乐观情境下预测,该药物用于减重与糖尿病的年销售额到2033年...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10